🌿 Herbs Info

Ginkgo

Ginkgo biloba

Ginkgo biloba, specifically the standardized extract EGb 761 (Tebonin/Tanakan), has strong evidence for the symptomatic treatment of mild-to-moderate dementia and mild cognitive impairment at 240 mg/day, with meta-analyses confirming significant improvements in cognition, neuropsychiatric symptoms, activities of daily living, and quality of life. However, two landmark mega-trials (GEM: n=3,069; GuidAge: n=2,854) conclusively demonstrated that EGb 761 does NOT prevent the development of dementia in elderly individuals. Tinnitus evidence is mixed: EGb 761 appears to help tinnitus as a concomitant symptom of dementia but NOT as a standalone primary condition. The bleeding risk historically associated with ginkgo appears to be overstated based on current controlled trial evidence. The EMA grants "well-established use" status for age-related cognitive impairment.

Ivy Leaf

Hedera helix

Ivy leaf extract is one of the best-evidenced herbal expectorants in European phytotherapy. The standardized extract EA 575 (marketed as Prospan) has been studied in over 65,000 patients across clinical and observational studies. It has a well-characterized molecular mechanism involving indirect beta-2 adrenergic receptor stimulation via the saponin alpha-hederin. It holds approvals from all three major European regulatory bodies (Commission E, ESCOP, EMA/HMPC) and is widely used in pediatric practice.

Kava

Piper methysticum

Kava is one of the best-studied herbal anxiolytics, with a positive Cochrane review (12 RCTs, n=700) and robust evidence from the standardized extract WS 1490. Its anxiolytic effects are mediated through GABA-A potentiation, monoamine reuptake inhibition, and sodium channel modulation, providing anxiolysis without the sedation or cognitive impairment of benzodiazepines. However, the herb's regulatory history is dominated by a hepatotoxicity scare beginning in 1999 that led to market withdrawal in Germany (2002) and across much of the EU. Subsequent analysis strongly suggests the liver injury cases were largely attributable to poor-quality plant material (tudei kava instead of noble kava), inappropriate extraction methods (acetone instead of ethanol or water), use of non-root plant parts, and possibly idiosyncratic/immunoallergic reactions. A German court overturned the ban, but it was reimposed in 2019, despite ongoing scientific criticism of the regulatory reasoning.

Herbal Medicine in Clinical Practice

Best practices for integrating herbal medicines into healthcare

Commission E Monographs

The Commission E was a German regulatory body that systematically evaluated herbal medicines and published detailed monographs with evidence-based safety and efficacy assessments. These monographs form the foundation of European phytotherapy.

Commission E: Germany's Herbal Medicine Authority

History and impact of the Commission E monographs on European phytotherapy

ESCOP & EMA/HMPC Monographs

The European Scientific Cooperative on Phytotherapy (ESCOP) and the EMA/HMPC provide modern evidence-based monographs for herbal medicines, representing the current European regulatory and scientific consensus.

ESCOP, EMA, and HMPC: European Regulatory Frameworks

Current regulatory systems for herbal medicines in Europe

Key Reference Texts

The foundational textbooks and monographs that form the scientific and clinical basis of European phytotherapy research and practice.

Key Reference Texts for Herbal Medicine

Important resources for studying European phytotherapy

Phytotherapy in Medical Practice

A practical guide to how European phytotherapy is integrated into clinical practice, medical education, pharmacy standards, and healthcare systems.